[{"id":6640,"regimens":[{"id":13268,"duration":{"id":7158,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11420,"name":"Low Molecular Weight Heparin","url":"cure-api2.ncats.io/v1/drugs/11420","rxNorm_id":null,"notes":null},"use_drug":[{"id":11692,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13268},{"id":11693,"answer":"In a novel combination with another drug","answer_other":"","regimen":13268},{"id":11979,"answer":"Other","answer_other":"For ARDS and COVID associated hypercoagulation","regimen":13268}],"created":"2020-12-01T22:45:30.257538Z","updated":"2020-12-07T14:58:30.569574Z","dose":null,"frequency":"Therapeutic Dosage","route":"","severity":"Inpatient","severity_detail":"Non-Invasive Ventilation","comments":null,"report":6640},{"id":13269,"duration":{"id":7159,"approximate_duration":"","dates_unknown":true},"drug":{"id":11421,"name":"Unfractionated Heparin","url":"cure-api2.ncats.io/v1/drugs/11421","rxNorm_id":null,"notes":null},"use_drug":[{"id":11694,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13269},{"id":11695,"answer":"In a novel combination with another drug","answer_other":"","regimen":13269},{"id":11980,"answer":"Other","answer_other":"For ARDS and COVID associated hypercoagulation","regimen":13269}],"created":"2020-12-01T22:45:30.265554Z","updated":"2020-12-07T14:58:30.570492Z","dose":"500 U/h, then 1000 IU/h","frequency":"","route":"","severity":"Inpatient","severity_detail":"Non-Invasive Ventilation","comments":null,"report":6640},{"id":13270,"duration":{"id":7160,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11408,"name":"Tissue plasminogen activator","url":"cure-api2.ncats.io/v1/drugs/11408","rxNorm_id":19,"notes":""},"use_drug":[{"id":11696,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13270},{"id":11697,"answer":"In a novel combination with another drug","answer_other":"","regimen":13270},{"id":11981,"answer":"Other","answer_other":"For ARDS and COVID associated hypercoagulation","regimen":13270}],"created":"2020-12-01T22:50:12.086943Z","updated":"2020-12-07T14:58:30.571310Z","dose":"2 mg/h, then 30mg over 15h","frequency":"","route":"","severity":"Inpatient","severity_detail":"Non-Invasive Ventilation","comments":null,"report":6640}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8710,"answer":"Clinical assessment","answer_other":"","report":6640},{"id":8711,"answer":"PCR","answer_other":"","report":6640}],"how_diagnosis":[{"id":14974,"answer":"Clinical assessment","answer_other":"","report":6640},{"id":14975,"answer":"Imaging","answer_other":"","report":6640},{"id":14976,"answer":"PCR","answer_other":"","report":6640}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4820,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6640}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-12-01T22:41:43.908971Z","updated":"2020-12-07T14:58:30.524381Z","title":"Successful use of tPA for thrombolysis in COVID related ARDS: a case series. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32617806,"doi":"10.1007/s11239-020-02208-2","article_url":"https://pubmed.ncbi.nlm.nih.gov/32617806/","pub_year":2020,"published_authors":"Goyal A\r\nSaigal S\r\nNiwariya Y\r\nSharma J\r\nSingh P","article_author_email":"abhishek.pulmed@aiimsbhopal.edu.in","journal":"Journal of thrombosis and thrombolysis","abstract":"We describe successful usage of low dose Tissue plasminogen activator (tPA) (30-50 mg) in three COVID19 critically ill patients, who were in worsening respiratory failure in-spite of being on therapeutic anticoagulation. All patients had respiratory rate > 40; FiO2 > 0.7(on NIV); PiO2/FiO2 ratio < 100 and D-dimer>1000 ng/ml. C.T. Pulmonary Angiography could not be done in these patients due to poor general condition, but 2D echo was normal and none of the patients was in shock. So there was no conventional indication of thrombolysis in these patients, yet after thrombolysis, we saw dramatic changes in oxygenation. All patients became off oxygen within 3-7 days and were discharged within 2 weeks. The whole idea was to prevent intubation, since mortality rates are very high in intubated COVID19 patients. tPA is associated with <1% risk of fatal bleed. In this unprecedented pandemic with high mortality rates, thrombolysis could be an effective and safe option in carefully selected critically ill patients of COVID19.          \r\n        Keywords:      \r\n                  Acute respiratory distress syndrome (ARDS); COVID19; Coagulopathy; Thrombolysis; Tissue plasminogen activator (tPA).","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"41-50 years","sex":"Male","ethnicity":null,"country_contracted":"India","country_treated":"India","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pulmonary micro-thrombosis, Pneumonia, Dyspnoea","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Reason for shifting from LMWH to UFH was to have better control over bleeding episodes.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11420,11408,11421]},{"id":6642,"regimens":[{"id":13273,"duration":{"id":7163,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11408,"name":"Tissue plasminogen activator","url":"cure-api2.ncats.io/v1/drugs/11408","rxNorm_id":19,"notes":""},"use_drug":[{"id":11702,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13273},{"id":11703,"answer":"In a novel combination with another drug","answer_other":"","regimen":13273}],"created":"2020-12-01T23:08:53.227842Z","updated":"2020-12-01T23:15:08.260537Z","dose":"50mg","frequency":"Over 3 Hours","route":"","severity":"ICU/Critical Care","severity_detail":"High flow nasal canula","comments":null,"report":6642},{"id":13274,"duration":{"id":7164,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11421,"name":"Unfractionated Heparin","url":"cure-api2.ncats.io/v1/drugs/11421","rxNorm_id":null,"notes":null},"use_drug":[{"id":11704,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13274},{"id":11705,"answer":"In a novel combination with another drug","answer_other":"","regimen":13274}],"created":"2020-12-01T23:08:53.236024Z","updated":"2020-12-01T23:15:08.266999Z","dose":"1000 IU/h","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"High flow nasal canula","comments":null,"report":6642}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8714,"answer":"Clinical assessment","answer_other":"","report":6642},{"id":8715,"answer":"PCR","answer_other":"","report":6642}],"how_diagnosis":[{"id":14980,"answer":"Clinical assessment","answer_other":"","report":6642},{"id":14981,"answer":"Imaging","answer_other":"","report":6642},{"id":14982,"answer":"PCR","answer_other":"","report":6642}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4822,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6642}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-12-01T23:07:50.220582Z","updated":"2020-12-01T23:15:08.252762Z","title":"Successful use of tPA for thrombolysis in COVID related ARDS: a case series. Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32617806,"doi":"10.1007/s11239-020-02208-2","article_url":"https://pubmed.ncbi.nlm.nih.gov/32617806/","pub_year":2020,"published_authors":"Goyal A\r\nSaigal S\r\nNiwariya Y\r\nSharma J\r\nSingh P","article_author_email":"abhishek.pulmed@aiimsbhopal.edu.in","journal":"Journal of thrombosis and thrombolysis","abstract":"We describe successful usage of low dose Tissue plasminogen activator (tPA) (30-50 mg) in three COVID19 critically ill patients, who were in worsening respiratory failure in-spite of being on therapeutic anticoagulation. All patients had respiratory rate > 40; FiO2> 0.7(on NIV); PiO2/FiO ratio < 100 and \r\n D dimer>1000 ng/ml. C.T. Pulmonary Angiography could not be done in these patients due to poor general condition, but 2D echo was normal and none of the patients was in shock. So there was no conventional indication of thrombolysis in these patients, yet after thrombolysis, we saw dramatic changes in oxygenation. All patients became off oxygen within 3-7 days and were discharged within 2 weeks. The whole idea was to prevent intubation, since mortality rates are very high in intubated COVID19 patients. tPA is associated with <1% risk of fatal bleed. In this unprecedented pandemic with high mortality rates, thrombolysis could be an effective and safe option in carefully selected critically ill patients of COVID19.          \r\n        Keywords:      \r\n                  Acute respiratory distress syndrome (ARDS); COVID19; Coagulopathy; Thrombolysis; Tissue plasminogen activator (tPA).","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"3","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Female","ethnicity":null,"country_contracted":"India","country_treated":"India","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Hypothyroid, Obese","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pulmonary micro-thrombosis, Pneumonia, fever, breathlessness, decreased appetite","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11408,11421]}]